Milestone Pharmaceuticals Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Montreal, Quebec, Canada
SEC filing record 1 source field available
Fiscal year end
31 December
Milestone Pharmaceuticals Inc. has filed 416 SEC EDGAR filings since 30 Jul 2007

SEC filing history

Showing 326-350 of 415 matching filings.

Per page
25
Current page
14
8-K File 001-38899

FORM 8-K

Filing date
23 Mar 2020
Reporting date
23 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
19 Mar 2020
Reporting date
18 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
19 Mar 2020
Reporting date
02 Mar 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-91001

AMENDMENT NO. 3 TO SCHEDULE 13D

Filing date
12 Mar 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 File 333-236971

FORM S-8

Filing date
06 Mar 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-91001

SCHEDULE 13G

Filing date
14 Feb 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91001

SC 13G/A filing

Filing date
14 Feb 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-91001

SC 13G filing

Filing date
14 Feb 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-91001

SC 13G

Filing date
11 Feb 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
24 Jan 2020
Reporting date
23 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
24 Jan 2020
Reporting date
23 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
24 Jan 2020
Reporting date
23 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
24 Jan 2020
Reporting date
23 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
13 Jan 2020
Reporting date
13 Jan 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-91001

SCHEDULE 13G FOR MILESTONE PHARMACEUTICALS INC. BY DOMAIN PARTNERS VIII, L.P.

Filing date
09 Jan 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
02 Jan 2020
Reporting date
30 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-38899

FORM 8-K

Filing date
17 Dec 2019
Reporting date
17 Dec 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-38899

FORM 8-K

Filing date
03 Dec 2019
Reporting date
29 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
27 Nov 2019
Reporting date
25 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-91001

AMENDMENT NO. 2 TO SCHEDULE 13D

Filing date
27 Nov 2019
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
22 Nov 2019
Reporting date
20 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
14 Nov 2019
Reporting date
12 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
14 Nov 2019
Reporting date
12 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
14 Nov 2019
Reporting date
12 Nov 2019
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .